Institutional members access full text with Ovid®

Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review

Anglemyer, Andrewa; Rutherford, George W.a; Easterbrook, Philippa J.b; Horvath, Taraa; Vitória, Marcob; Jan, Michaelc; Doherty, Meg C.b

doi: 10.1097/QAD.0000000000000232
Adults and Adolescents
Open Access Icon

Objectives: The objective of this review was to update evidence on when to initiate antiretroviral therapy (ART) to inform revision of the 2013 WHO guidelines for ART in low and middle-income countries.

Design: A systematic review and meta-analysis.

Methods: We comprehensively searchescohorts. Outcomes were mortality, clinical progression, virologic failure, immunologic recover, and severe adverse events. We pooled data across studies and estimated summary effect sizes. We graded the quality of evidence from the literature for each outcome.

Results: We identified 24 studies; 3 were RCTs. Studies found reduced risk of mortality [1 RCT: hazard ratio 0.77, 95% confidence interval (CI) 0.34–1.76; 13 cohorts: relative risk (RR) 0.66, 95% CI 0.55–0.79], progression to AIDS or death (2 RCTs: RR 0.48, 95% CI 0.26–0.91; 9 cohorts: RR 0.70, 95% CI 0.40–1.24) and diagnosis of a non-AIDS-defining illness (1 RCT: RR 0.14, 95% CI 0.03–0.64; 1 cohort: RR 0.47, 95% CI 0.23–0.98), and an increased risk of grade 3/4 laboratory abnormalities in patients initiating ART at at least 350 cells/μl (1 RCT: RR 1.49, 95% CI 1.25–1.77). The quality of evidence was low or very low for clinical outcomes due to few events and imprecision, and high for adverse events.

Conclusions: Our findings contributed to the evidence base for the revised 2013 WHO guidelines on ART, which recommend initiating ART at CD4+ T-cell counts of 350–500 cells/μl, but not above 500 cells/μl compared to initiating it later when CD4+ T-cell counts fall below 350 cells/μl.

aCochrane HIV/AIDS Group, Global Health Sciences, University of California, San Francisco, San Francisco, California, USA

bHIV Department, World Health Organization, Geneva, Switzerland

cTemple University School of Medicine, Philadelphia, Pennsylvania, USA.

Correspondence to George W. Rutherford, MD, AM, Global Health Sciences, University of California, San Francisco, 50 Beale Street, 12th floor, San Francisco, CA 94105, USA. Tel: +1 415 597 9108; e-mail: grutherford@psg.ucsf.edu.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

© 2014 Lippincott Williams & Wilkins, Inc.